Mynosys Cellular Devices, which manufactures the Zepto cataract surgery device, has secured $25 million in a funding round led by investment firm Decheng Capital.
The California-based ophthalmic technology company intends to use the funds to accelerate its growth in the US market and also to build a strong and sustainable R&D, manufacturing and commercial organization.
Mynosys Cellular Devices has selected Rob Thornhill, a veteran ophthalmology industry executive as its CEO.
Rob Thornhill said: “I am excited to work with the Zepto team to deliver on the promise this device brings to cataract surgery. It is gratifying that Decheng Capital appreciates the tremendous value and potential of the Zepto technology, which has already captured the support of some of the world’s most prominent ophthalmic surgeons. It will be an honor to work with those thought leaders to build on the early success of the device.”
Prior to joining Mynosys Cellular Devices, Rob Thornhill was the founding CEO of Tear Film Innovations. Rob Thornhill comes with 30 plus years of experience in marketing, sales, and general management in the healthcare sector.
In addition to overseeing the day-to-day operations of the ophthalmic technology company, Rob Thornhill will be responsible for product improvement and expansion of the US sales and marketing team.
According to Mynosys Cellular Devices, its Zepto cataract surgery device offers a safe, predictable, effective new method to automate the anterior capsulotomy, which enables surgeons cut down risk, increase edge strength, and enhance precision in cataract procedures.
David F. Chang – a cataract surgeon said: “Zepto is an innovative capsulotomy technology that can affordably be a part of everyone’s surgical armamentarium. Expanding the Mynosys sales and training staff should increase global access to this device, particularly in practices where a less expensive method of automating the capsulotomy is desirable.”